Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T90648
|
||||
| Former ID |
TTDR01373
|
||||
| Target Name |
mRNA of B-Raf
|
||||
| Gene Name |
BRAF
|
||||
| Synonyms |
Proto-oncogene B-Raf (mRNA); Serine/threonine-protein kinase B-raf (mRNA); p94 (mRNA); v-Raf murine sarcoma viral oncogene homolog B1 (mRNA); BRAF
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
| Parkinson's disease [ICD9: 332; ICD10: G20] | |||||
| Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
| BioChemical Class |
Kinase
|
||||
| Target Validation |
T90648
|
||||
| UniProt ID | |||||
| EC Number |
EC 2.7.11.1
|
||||
| Sequence |
MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEH
IEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTV TSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRK TFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPI PQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR DRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSP GPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDV AVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHH LHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATV KSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNIN NRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARS LPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH |
||||
| Drugs and Mode of Action | |||||
| Inhibitor | 2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine | Drug Info | [527954] | ||
| 2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine | Drug Info | [527954] | |||
| BIIB-024 | Drug Info | [543525] | |||
| compound 2 | Drug Info | [533265] | |||
| L-779450 | Drug Info | [527836] | |||
| PLX-4720 | Drug Info | [531679] | |||
| PLX-ORI3 | Drug Info | [543525] | |||
| Pyrazolo[1,5-a]pyrimidine-3-carboxylate | Drug Info | [530074] | |||
| RG7304 | Drug Info | [551608] | |||
| ZM-336372 | Drug Info | [529039] | |||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | MAPK signaling pathway | ||||
| ErbB signaling pathway | |||||
| Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Chemokine signaling pathway | |||||
| FoxO signaling pathway | |||||
| mTOR signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Focal adhesion | |||||
| Natural killer cell mediated cytotoxicity | |||||
| Long-term potentiation | |||||
| Neurotrophin signaling pathway | |||||
| Serotonergic synapse | |||||
| Long-term depression | |||||
| Regulation of actin cytoskeleton | |||||
| Insulin signaling pathway | |||||
| Progesterone-mediated oocyte maturation | |||||
| Alcoholism | |||||
| Hepatitis C | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| Colorectal cancer | |||||
| Renal cell carcinoma | |||||
| Pancreatic cancer | |||||
| Endometrial cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Thyroid cancer | |||||
| Melanoma | |||||
| Bladder cancer | |||||
| Chronic myeloid leukemia | |||||
| Acute myeloid leukemia | |||||
| Non-small cell lung cancer | |||||
| NetPath Pathway | IL-7 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| Integrin signalling pathway | |||||
| Interleukin signaling pathway | |||||
| PDGF signaling pathway | |||||
| T cell activation | |||||
| VEGF signaling pathway | |||||
| Ras Pathway | |||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | CDC42 signaling events | ||||
| mTOR signaling pathway | |||||
| Ras signaling in the CD4+ TCR pathway | |||||
| ErbB1 downstream signaling | |||||
| PDGFR-beta signaling pathway | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Trk receptor signaling mediated by the MAPK pathway | |||||
| PathWhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | ||||
| Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||||
| Reactome | Spry regulation of FGF signaling | ||||
| Frs2-mediated activation | |||||
| ARMS-mediated activation | |||||
| CREB phosphorylation through the activation of Ras | |||||
| RAF activation | |||||
| MAP2K and MAPK activation | |||||
| Negative feedback regulation of MAPK pathway | |||||
| Negative regulation of MAPK pathway | |||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Serotonin HTR1 Group and FOS Pathway | |||||
| Senescence and Autophagy in Cancer | |||||
| Regulation of Actin Cytoskeleton | |||||
| EGF/EGFR Signaling Pathway | |||||
| MAPK Cascade | |||||
| MAPK Signaling Pathway | |||||
| Bladder Cancer | |||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Polycystic Kidney Disease Pathway | |||||
| Corticotropin-releasing hormone | |||||
| B Cell Receptor Signaling Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Integrated Breast Cancer Pathway | |||||
| Signaling by FGFR | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| Integrin-mediated Cell Adhesion | |||||
| References | |||||
| Ref 527836 | Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. Epub 2005 Nov 2.The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. | ||||
| Ref 527954 | J Med Chem. 2006 Jan 12;49(1):407-16.Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. | ||||
| Ref 529039 | Biochem J. 2007 Dec 15;408(3):297-315.The selectivity of protein kinase inhibitors: a further update. | ||||
| Ref 530074 | Bioorg Med Chem Lett. 2009 May 15;19(10):2735-8. Epub 2009 Mar 28.Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. | ||||
| Ref 531679 | Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. | ||||
| Ref 533265 | Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib. ACS Chem Biol. 2015 Sep 18;10(9):2099-107. | ||||
| Ref 543525 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.